For metastatic NSCLC patients (stage IV), targeted therapy is typically used for patients whose tumors carry driver gene mutations (e.g., EGFR, ALK, MET, ROS1, KRAS) but they are only present in a small proportion of NSCLC patients (around 25%) [10,14,15]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.